Jean Norden
Overview
Explore the profile of Jean Norden including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
286
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lin W, Fordham S, Hungate E, Sunter N, Elstob C, Xu Y, et al.
Nat Commun
. 2022 Jan;
13(1):2.
PMID: 34983928
No abstract available.
2.
Lin W, Fordham S, Hungate E, Sunter N, Elstob C, Xu Y, et al.
Nat Commun
. 2021 Oct;
12(1):6233.
PMID: 34716350
Acute myeloid leukemia (AML) is a hematological malignancy with an undefined heritable risk. Here we perform a meta-analysis of three genome-wide association studies, with replication in a fourth study, incorporating...
3.
Crossland R, Norden J, Ghimire S, Juric M, Pearce K, Lendrem C, et al.
Front Immunol
. 2021 Apr;
12:639171.
PMID: 33790910
Acute graft vs. host disease (aGvHD) is a frequent complication following allogeneic haematopoeitic transplantation (HSCT). Despite recent advances, there are no universally accepted biomarkers to determine development of aGvHD. MicroRNAs...
4.
Norden J, Pearce K, Irving J, Collin M, Wang X, Wolff D, et al.
Int J Immunogenet
. 2018 Jul;
PMID: 30043490
Haematopoietic stem cell transplantation (HSCT) remains the only cure for most haematological malignancies, however, the mortality rate remains high. Complications after HSCT include relapse, graft versus host disease (GvHD), graft...
5.
Atarod S, Norden J, Bibby L, Janin A, Ratajczak P, Lendrem C, et al.
Front Immunol
. 2018 Jul;
9:1485.
PMID: 30042760
Allogeneic hematopoietic stem cell transplantation is a curative treatment for numerous hematological malignancies. However, acute graft-versus-host disease (aGvHD) is a major complication affecting 40-70% of all transplant patients, whereby the...
6.
Crossland R, Norden J, Juric M, Pearce K, Lendrem C, Bibby L, et al.
Front Immunol
. 2017 Nov;
8:1446.
PMID: 29176973
Acute graft-versus-host disease (aGvHD) is a major cause of adverse outcome in hematopoietic stem cell transplantation (HSCT), with a high incidence (20-50%). A novel, non-invasive diagnostic test to predict for...
7.
Dickinson A, Norden J, Li S, Hromadnikova I, Schmid C, Schmetzer H, et al.
Front Immunol
. 2017 Jun;
8:496.
PMID: 28638379
The success of hematopoietic stem cell transplantation (HSCT) lies with the ability of the engrafting immune system to remove residual leukemia cells a graft-versus-leukemia effect (GvL), caused either spontaneously post-HSCT...
8.
Gam R, Shah P, Crossland R, Norden J, Dickinson A, Dressel R
Front Immunol
. 2017 Apr;
8:380.
PMID: 28421078
The outcome of hematopoietic stem cell transplantation (HSCT) is controlled by genetic factors among which the leukocyte antigen human leukocyte antigen (HLA) matching is most important. In addition, minor histocompatibility...
9.
Crossland R, Norden J, Juric M, Green K, Pearce K, Lendrem C, et al.
Front Immunol
. 2017 Apr;
8:308.
PMID: 28392786
Acute graft-versus-host disease (aGvHD) is the most frequent and serious complication following hematopoietic stem cell transplantation (HSCT), with a high mortality rate. A clearer understanding of the molecular pathogenesis may...
10.
Jalapothu D, Boieri M, Crossland R, Shah P, Butt I, Norden J, et al.
Front Immunol
. 2016 Oct;
7:361.
PMID: 27695455
MicroRNAs (miRNA) have emerged as central regulators of diverse biological processes and contribute to driving pathology in several diseases. Acute graft-versus-host disease (aGvHD) represents a major complication after allogeneic hematopoietic...